Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: A prospective study

• Published in: The Journal of infection Vol. 62; no. 5; pp. 406 - 409
• Main Authors: Manosuthi, Weerawat, Lueangniyomkul, Aroon, Mankatitham, Wiroj, Chimsuntorn, Sukanya, Tantanathip, Preecha, Thongyen, Supeda, Suntisuklappon, Busakorn, Nilkamhang, Samruay, Sungkanuparph, Somnuek
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Ltd 01.05.2011; Elsevier
• Subjects: Adenine - administration & dosage; Adenine - adverse effects; Adenine - analogs & derivatives; Adult; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - adverse effects; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiretroviral Therapy, Highly Active - adverse effects; Antiretroviral Therapy, Highly Active - methods; Antiviral agents; Biological and medical sciences; Cohort Studies; Female; General aspects; HIV Infections - drug therapy; Human viral diseases; Humans; Infectious Disease; Infectious diseases; Lamivudine - administration & dosage; Lamivudine - adverse effects; Lipid Metabolism - drug effects; Male; Medical sciences; Middle Aged; Organophosphonates - administration & dosage; Organophosphonates - adverse effects; Pharmacology. Drug treatments; Prospective Studies; Stavudine - administration & dosage; Stavudine - adverse effects; Tenofovir; Treatment Outcome; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Immunopathology; Purine nucleotide; Antiretroviral agent; Acyclic nucleotide; RNA-directed DNA polymerase; Enzyme; Transferases; Enzyme inhibitor; Lamivudine; AIDS; Organic phosphonate; Nucleotide analog; Stavudine; Immune deficiency; Long term; Infection; Tenofovir; Nucleotidyltransferases; Dideoxynucleoside; Reverse transcriptase inhibitor; Viral disease; Nucleoside analog; Antiviral; Pyrimidine nucleoside
• ISSN: 0163-4453; 1532-2742
• DOI: 10.1016/j.jinf.2011.02.012